PYC Therapeutics Limited ( (AU:PYC) ) has provided an announcement.
PYC Therapeutics Limited has announced an accelerated non-renounceable entitlement offer, proposing to issue up to 116,651,930 ordinary fully paid securities. This initiative is part of the company’s strategy to enhance its capital structure and support its ongoing development programs, potentially strengthening its position in the biotechnology industry and offering significant implications for its stakeholders.
More about PYC Therapeutics Limited
PYC Therapeutics Limited operates in the biotechnology industry, focusing on developing innovative peptide-based therapeutics. The company is engaged in creating treatments for inherited retinal diseases, emphasizing its commitment to addressing unmet medical needs in this specific market segment.
YTD Price Performance: -2.65%
Average Trading Volume: 405,310
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$599.6M
See more data about PYC stock on TipRanks’ Stock Analysis page.